Biomolecules, Vol. 12, Pages 1788: Galectin-3 and Myeloperoxidase May Monitor Cancer-Therapy-Related Cardiotoxicity? A Systematic Review and Meta-Analysis

Figure 1. PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only.

Biomolecules 12 01788 g001 Figure 2. Quality assessment using the Newcastle-Ottawa Scale for cohort studies [13,14,15,16,17,18,19,20]. Biomolecules 12 01788 g002 Figure 3. Overall and individual study estimates of the weighted mean difference of Galectin-3 are shown in patients receiving cancer treatment. Parallelogram boxes for weighted mean difference and horizontal lines represent 90% confidence interval (CI). Subgroup analyses were carried out independently for country (A), the presence of doxorubicin (B) and measurement (C) [14,15,17,18,19]. Biomolecules 12 01788 g003aBiomolecules 12 01788 g003b Figure 4. Cancer-therapy-related cardiotoxicity as measured by a standardized left ventricular ejection fraction decrease with no considerable Galectin-3 change. Parallelogram boxes for hazard ratio, and horizontal lines represent 90% confidence interval (CI) [15,19]. Biomolecules 12 01788 g004 Figure 5. (A) Overall and individual study estimates of the standardized mean difference of MPO are shown in patients receiving cancer treatment. Parallelogram boxes for standardized mean difference, and horizontal lines represent 90% confidence interval (CI). (B) Cancer-therapy-related cardiotoxicity as measured by a standardized left ventricular ejection fraction decrease with significant MPO change. Parallelogram boxes for hazard ratio, and horizontal lines represent 90% confidence interval (CI) [13,16,17,19,20]. Biomolecules 12 01788 g005

Figure 6. The potential mechanism of MPO increasing after cancer therapy. MPO: myeloperoxidase; NETs: neutrophil extracellular traps.

Biomolecules 12 01788 g006

Table 1. Study Characteristics. Values are expressed as mean ± SD or median [interquartile range] for continuous variables. LVEF: Left Ventricular Ejection Fraction; gal-3: galectin-3; MPO: myeloperoxidase. +: The main outcome event occurred, but the number of events was not extracted; —: No accurate data were extracted. ①②: Age distribution of different interventions.

Table 1. Study Characteristics. Values are expressed as mean ± SD or median [interquartile range] for continuous variables. LVEF: Left Ventricular Ejection Fraction; gal-3: galectin-3; MPO: myeloperoxidase. +: The main outcome event occurred, but the number of events was not extracted; —: No accurate data were extracted. ①②: Age distribution of different interventions.

Study CharacteristicsAuthorYearSample
SizeStudy TypeCountryAge
(Mean; Interquartile Range/SD)Cancer TypeIntervention
(Treatment Modality)Follow-Up
(Months)Baseline LVEF %
(Mean; Interquartile Range/SD)Biomarker ExaminedOutcome Events (n)Associated Outcome (HR)B. G. Demissei et al. [13]2020323ProspectiveUSA48 (41–57)breast cancerdoxorubicin + Trastuzumab44.453 (51–56)%MPO49MPO: 1.1
(0.92–1.31)S. R. Patel et al. [14]20211160ProspectiveUSA52.2 ± 9.6breast CancerAnthracyclines32.4—gal-3+—W. van Boxtel et al. [15]201555ProspectiveNetherlands52.8 ± 8.5breast cancerdocetaxel + doxorubicin +
cyclophosphamide (TAC)12—gal-35gal-3: 3.19
(0.46, 22.20)Lakhani HV et al. [16]202117ProspectiveUSA57.6 ± 4.5invasive ductal carcinomaAnthracyclines662.9 ± 1.2%MPO4—M. R. B. Wanderley et al. [17]2022174ProspectiveBrazil50.4 ± 9.5breast CancerAnthracyclines6—gal-3, MPO26—G.Gulati et al. [18]2017121ProspectiveNorway① Epirubicin = 400 mg/m2: 51.0 (42.0, 59.0) n = 27
② Epirubicin < 400 mg/m2: 48.5 (43.8, 58.0) n = 94breast cancerAnthracyclines3.263.3 ± 4.0%gal-31—B. Ky et al. [19]201478ProspectiveUSA50.0 (42.0–56.8)breast cancerAnthracyclines364 (61–68)%gal-3, MPO+gal-3: 1.33 (0.86–2.05)
MPO: 1.34 (1.00–1.80)V. K. Todorova et al. [20]202051ProspectiveUSA52.2 ± 11.5breast cancerdoxorubicin0.564.5 ± 7.0%MPO+—

留言 (0)

沒有登入
gif